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Abstract The indication for microvascular free tissue trans-
fer is usually exposure of vital structures, bone defect, or loss
of function. Radical debridement and control of infection is a
prerequisite for any kind of reconstructive procedure. This is
especially true for untidy wounds in industrial or agricultural
settings; in these, one should not hesitate to debride any tissue
which is not obviously viable. Aggressive surgical debride-
ment should be performed before flap coverage. Some
organisms, however, fail to be eradicated by mechanical
debridement as they are particularly pathogenic or embedded
in the tissues. Perforator flaps are currently recommended
for soft tissue coverage of the upper limb, for their pliability
and the low morbidity of the donor site. A case of traumatic
deglovement injury of an upper arm is presented. After free
flap coverage, it was complicated by a rare and highly
pathogenic fungal infection. Successful soft tissue reconstruc-
tion obtained with a chimeric free flap was compromised
by an expanding fungal infection ultimately leading to limb
amputation.
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Introduction
A large defect can be defined as any defect which cannot be
closed primarily or by simple random local flaps [6].
Microsurgical free tissue transfer is currently the gold
standard for coverage and limb salvage of extensive defects
of the upper extremity, if they are too large for local flap
cover.
The indication for microvascular free tissue transfer is
usually exposure of vital structures, bone defect, and loss of
function. Surgery may be performed acutely a few days
after the trauma or within 2 weeks [3, 10].
Early wound cover and infection control, repair of
damaged structures, and preservation of limb function are
the primary goals [5], but donor site morbidity and contour
characteristics are becoming more and more important with
the improvement in surgical techniques [6]. Radical
debridement and control of infection is a prerequisite for
any kind of reconstructive procedure. This is especially true
for untidy wounds in industrial or agricultural settings; with
these, one should not hesitate to debride any tissue which is
not obviously viable.
Mucormycosis, also referred to as phycomycosis or
zygomycosis, is a rare but aggressive opportunistic fungal
infection, which is now emerging in importance with the
increasing prevalence of immunosuppressive conditions and
metabolic states. It is caused by a group of ubiquitous
saprophytic organisms of the class Zygomycetes and order
Mucorales, which comprises nine genera. Species of Rhizopus
Mucor and Absidia are most frequently isolated in infected
human tissue. Infection can be acquired by inhalation,
ingestion, or the deposition of spores in wounds, and the
fungi give rise to pathogenic lesions as a result of invasion
and growth within the lumen and walls of major blood
vessels, with ensuing thromboembolism which can cause
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ischemia and tissue necrosis. There are several clinical
variants: rhino-orbital-cerebral, pulmonary, cutaneous, gas-
trointestinal, and disseminated. The rhino-orbital-cerebral
and pulmonary forms present most commonly and, together
with disseminated disease, are associated with the highest
mortality, ranging from 78% to 100%. Cutaneous disease
comprises less than 10% of all cases and is associated with
the best prognosis, with less than 10% mortality [13].
The clinical appearance of cutaneous mucormycosis is
insufficient for diagnosis because the clinical manifesta-
tions generally do not differ from other soft tissue
infections. Similar lesions can be produced by infections
with Pseudomonas, Aspergillus, Histoplasma, Cryptococcus,
Aeromonas hydrophilia, vasculitis, pyoderma gangrenosum,
and other necrotizing infections [9]. Tissue biopsy is
essential. The appearance of irregularly shaped, broad,
nonseptate, twisted, ribbon-like thick-wall fungal hyphae
(10–20 μm) with right angle branching is classic [9]. A
characteristic histological finding of mucormycosis is hyphal
invasion of the blood vessels with occlusion, causing a
constellation of thrombosis, infarction, ischemia, necrosis,
and hemorrhage.
There are no clinical surgical guidelines to treat
cutaneous mucormycosis. There are reports of primary
cutaneous mucormycosis being treated with a therapy
ranging from chemotherapy without surgery to radical
approaches including amputation. The combined surgical
and medical antifungal chemotherapeutic approach to
treatment remains the standard of care [9, 13].
The antifungal drug of choice is amphotericin B in the
highest tolerable doses, usually 1–1.5 mg/kg daily. Higher
doses of liposomal amphotericin can be used, usually 5–
8 mg/kg, and doses as high as 15 mg/kg daily have also been
advocated. Imidazole drugs, such as itraconazole or vorico-
nazole, have also been used. New treatment options are
emerging with triazole antifungal agents such as posacona-
zole (200 mg four times daily orally),this is a broad-spectrum
antifungal agent which has shown even greater efficacy and
less toxicity than amphotericin, and has been suggested as
the drug of choice for mucormycosis [9].
Case report
A 38-year-old farmer was admitted to our hospital after
traumatic deglovement of almost his entire arm in a
Brussels sprout-harvesting machine. Two transverse frac-
tures of the radius and ulna were reduced and fixed with
external fixation. There was also an intra-articular fracture
of the radius with carpal subluxation (Fig. 1). Wide
debridement of the wound was performed and high dose
intravenous antimicrobial therapy was instigated using
amoxicillin/clavulanate potassium.
Fig. 1 Preoperative appearance of the defect
Fig. 2 Preoperative markings of the flap
Fig. 3 Intraoperative view of flap harvesting
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Six days later the patient underwent debridement of the
lesion and the defect was covered with a free “chimera” flap
[7] (Fig. 2). This was a thoracodorsal artery flap with a
segment of latissimus dorsi muscle to cover such a large
defect. Unfortunately, there was no satisfactory perforator
found during the dissection and the flap was harvested on the
lateralis thoracic artery and its comitant veins [8] (Fig. 3).
This flap had a skin paddle together with the serratus fascia
which was skin grafted (Fig. 4). The anastomosis of the
artery was performed end-to-side to the radial artery and the
vein end-to-side to a superficial vein.
Three days after surgery, a fungal infection by Mucormy-
cosis was discovered and was treated immediately with
amphotericin B (Fig. 5). The treatment with amphotericin B
was suspended after 7 days due to impending renal failure. A
specific antimicotic agent targeted against Mucormycosis+,
still under investigation for regulatory approval, posacona-
zole [11] was started to control the fungal spread.
Successful use of this agent has already been described as
a treatment of patients with Mucormycosis infection which
was unresponsive to systemic administration of amphoter-
icin B [12]. Ten days after the reconstruction there was a
rapid progression and deterioration of the infection; wound
exploration showed fungal contamination and discharge
engulfing the entire wounds (Fig. 6). There was obvious
fungal infection within the radius and ulna. The flap was
viable, though surrounded and invaded by fungus (Fig. 7).
After multiple debridement efforts an above elbow ampu-
tation was performed as a life saving procedure.
Discussion
Microsurgical free tissue transfer to reconstruct the upper
extremity allows repair of significant soft tissue defects. A
wide variety of free flaps are available for reconstruction of the
Fig. 4 Immediate postoperative view: full cover of the defect
Fig. 5 Persistent infection
Fig. 6 Spreading of the fungal infection (perioperative view)
Fig. 7 Spreading of the fungal infection (closer view)
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large defects of this area. The size and location of the defect,
and denuded structure are important factors, but the general
status of the patient, his expectation, and the socioeconomic
level should be considered in the planning of surgery [6].
Compound (chimeric) flaps can be used when different
structures are necessary, such as vascularized bone, tendon
or fascia; or when there is a need for filling up a defect.
A combined flap based on the chimeric concept consists
of two different tissues, each having their own pedicle [6, 7].
Aggressive surgical debridement, following the concepts
outlined by Hallock [5], should be performed before flap
cover. Some organisms however fail to be eradicated by
mechanical debridement as they are particularly pathogenic
or embedded in the tissues.
In untidy wounds infected by Mucormycosis surgical
management is almost always required, but the extent of
debridement required for cure is often unclear. Few cases of
surgical treatment of cutaneous mucormycosis are reported in
the literature, and no uniform plan of treatment has been
suggested. Currently, no clinical guidelines exist to assist the
clinician in the surgical treatment of this potentially fatal
disease.
Among all forms of mucormycosis, cutaneous mucormy-
cosis is a relatively uncommon presentation and represents
less than 10% of reported cases. It often occurs in patients
who have sustained some form of insignificant superficial
soft-tissue trauma, where it is supposed that the fungal
spores, present in the skin, are deposited into the skin and
deeper subcutaneous layers. The trauma need not be massive
and may be as benign as an insect bite, intramuscular
injection, or the use of contaminated elastic tape [9].
Primary cutaneous mucormycosis displays a broad
spectrum of clinical disease, ranging from contamination to
rapidly progressive gangrenous cellulitis, the latter usually
indicating an immunocompromised host. Cutaneous mucor-
mycosis is contracted either as a primary skin disease from
direct inoculation, or secondarily via hematogenous metas-
tasis from a pre-existing noncutaneous infection in another
organ system. The secondary cutaneous form of mucormy-
cosis is a manifestation of disseminated disease [9].
Cutaneous mucormycosis has been described by some as
manifesting two clinical presentations: a subacute “super-
ficial” form and a “gangrenous” form. If left untreated, this
form of mucormycosis can reportedly disseminate hema-
togenously into the other, more severe form of the disease.
“Gangrenous mucormycosis” has been described as the
more severe form.
The mortality of Mucormycosis is 60% in patients
treated only with systemic antimycotic agents, compared
with 11% in patients who undergo surgical treatment [4]. A
review of the literature yields a survival rate of only
approximately 33% after “radical surgical excision” or
amputation and amphotericin B administration [12].
In the literature, clinically nonspecific language regarding
surgical recommendations such as “conservative debride-
ment”, “radical surgical debridement”, “wide excision”,
“radical surgery”, “aggressive debridement”, and “extensive
surgical debridement” are used [2]. Reports in the literature
suggest that although superficial mucormycosis can be
treated with conservative surgical excision, gangrenous
mucormycosis must be excised widely [9].
From a surgical standpoint, the distinction between super-
ficial and gangrenous forms of mucormycosis may be a
spurious one. The combined surgical and medical antifungal
chemotherapeutic approach to treatment remains the standard
of care [9]. The classic school of thought conveying
musculocutaneous flap coverage [3] for untidy and complex
extremity soft tissue defects is being increasingly challenged.
Comparable control of infection and stable wound coverage is
currently achieved with perforator flaps and fasciocutaneous
flaps [1]. Even after aggressive debridement and early soft
tissue cover infection may lead to failure of the reconstruction
procedure in some cases [1, 5, 10]. Refinements in
microvascular surgery allow elegant and functionally effective
options for limb reconstruction, but an adequate control of
infection is the key point for the success of the treatment. A
judicious radical debridement and effective antimicrobial or
antifungal therapy is essential for limb salvage.
In this case, wide surgical debridement was performed
before flap cover, a progressively disseminating fungal
infection was encountered.
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